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Background: The proper development and implementation of point-of-care (POC) diagnostics 
requires knowledge of the perceived requirements and barriers to their implementation. To 
determine the current requirements and perceived barriers to the introduction of POC diagnostics 
in the field of medical microbiology (MM)-POC a prospective online survey (TEMPOtest-QC) 
was established.
Methods and results: The TEMPOtest-QC survey was online between February 2011 and 
July 2012 and targeted the medical community, POC test diagnostic manufacturers, general 
practitioners, and the general public. In total, 293 individuals responded to the survey, including 
91 (31%) medical microbiologists, 39 (13%) nonmedical microbiologists, 25 (9%) employees 
of POC test manufacturers, and 138 (47%) members of the general public. Responses were 
received from 18 different European countries, with the largest percentage of these living in 
The Netherlands (52%). The majority (.50%) of medical specialists regarded the development 
of MM-POC for blood culture and hospital acquired infections as “absolutely necessary”, but 
were much less favorable towards their use in the home environment. Significant differences in 
perceptions between medical specialists and the general public included the: (1) Effect on quality 
of patient care; (2) Ability to better monitor patients; (3) Home testing and the doctor-patient 
relationship; and (4) MM-POC interpretation. Only 34.7% of the general public is willing to 
pay more than €10 ($13) for a single MM-POC test, with 85.5% preferring to purchase their 
MM-POC test from a pharmacy.
Conclusion: The requirements for the proper implementation of MM-POC were found to be 
generally similar between medical specialists and POC test kit manufacturers. The general public 
was much more favorable with respect to a perceived improvement in the quality of healthcare 
that these tests would bring to the hospital and home environment.
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Introduction
Progress in the field of rapid and point-of-care (POC) diagnostics has been relatively 
slow, especially with respect to medical microbiology (MM) and the diagnosis of 
infectious diseases.1 In particular, the culture of microorganisms such as bacteria and 
fungi on solid or liquid growth medium still remains the “gold standard” by which 
POC diagnostic tests in MM (MM-POC) are compared.2 However, the identification 
of pathogens by culture, as well as the confirmation of their antimicrobial sensitivity 
profiles, are time consuming and require the skills of dedicated and trained medical 
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laboratory personnel. Surrogate markers of infection are 
becoming available as rapid diagnostics for the determina-
tion of the presence or absence of an infection, including the 
measurement of C reactive protein and procalcitonin. More-
over, there is evidence to suggest that these surrogate markers 
may be useful in the detection of an infection in seriously 
ill patients in the nosocomial environment.3–6 Additionally, 
specific molecular and antibody based diagnostic methods are 
becoming more readily available in many medical disciplines, 
including virology, emergency medicine, etc.7,8 However, 
POC test (POCT) manufacturers have generally been slow 
in developing POC devices for the detection of infectious 
diseases, particularly for infections caused by bacterial and 
fungal pathogens, even though the development of such 
diagnostic devices would facilitate the rapid identification of 
these infectious agents (if present) and allow better targeted 
prescribing of suitable antimicrobial therapy.8 Further, the 
largest trend in the field of rapid microbiological diagnos-
tics currently involves the evaluation and validation of new 
technologies within the medical microbiology laboratory 
per se, particularly the evaluation and validation of nucleic 
acid amplification technologies and mass spectrophotometric 
methods. This means that there still remains a large untapped 
market for the introduction of POC microbiological diagnos-
tics for such target audiences as professional nonmicrobiolo-
gist medical professionals, general practitioners and even 
patients (within their own homes). The use of POC devices 
by the above mentioned target groups would provide tangible 
benefits for all concerned, including more accurate, rapid, 
and cheaper diagnosis of microbiological infections, whilst 
providing accompanying advantages with respect to national 
healthcare budgets; eg, by facilitating earlier discharge from 
hospital and helping reduce the use of staff and equipment,9–11 
and for example by shifting the burden of healthcare from 
healthcare providers to the actual patients themselves. Fur-
ther, such market developments could provide significant 
advances with respect to limiting the ever growing threat of 
antimicrobial resistance and its impact on patient morbidity 
and mortality.12,13 In fact, the administration of suitable anti-
biotic therapy in the early onset of an infectious disease has 
been shown to improve the outcome of critically ill patients, 
with guidelines being available for the prescription of empiri-
cal antimicrobial therapy; ie, the prescribing of antimicrobial 
therapy before culture results become available.14 Moreover, 
the inappropriate use of antibiotics is closely linked to the 
development of antibiotic resistant microorganisms,15 and 
importantly, antibiotics are ineffective when used to treat 
viral infections. Further, the global increasing prevalence of 
antimicrobial resistance has not gone unnoticed by regula-
tory bodies such as the National Institute of Health and the 
World Health Organization.
The European Union is also facing up to its responsi-
bilities with respect to infectious disease diagnosis and the 
provision of improved healthcare to European citizens, having 
funded several projects that have investigated the develop-
ment and potential of rapid and POC infectious disease diag-
nostics. In particular, the “TEMPOtest-QC” project (www.
TEMPOtest-QC.eu) was designed to help “fill the current 
gap between microbiological POC testing technologies and 
actual clinical need”, and provide a “toolkit” (biobank of 
specimens, bacterial isolates, facilities and expertise, etc)16 
to help small and medium-sized enterprises (SME) evaluate 
and validate new technologies during the development of 
MM-POC diagnostics. In this respect, one of the main tasks 
of the project was to help stakeholders (medical professionals, 
general practitioners, developers and manufacturers, and the 
general public) understand the perceptions and requirements 
for MM-POC diagnostics within hospital, general surgery, 
and home environments. In turn, the knowledge from this 
study will help the stakeholders to better understand the 
requirements and potential hurdles to the introduction of 
MM-POC devices into healthcare environments,17,18 be it the 
hospital laboratory, by the bedside, at the general practitio-
ner’s surgery, or even within the patient’s own home.
Methods
survey
As part of the TEMPOtest-QC project goals, an online 
survey was established in order to determine the views and 
perceived requirements of European citizens to infectious 
disease (bacterial/fungal) MM-POC testing (Supplemental 
Data Appendix S1). For some questions multiple answers were 
allowed, which means that for some questions the number of 
responses may be greater than the number of respondents. Tar-
get groups for the survey were: (1) hospital medical microbiol-
ogists, including medical microbiology laboratory technicians; 
(2) nonmedical microbiology specialists (hospital doctors and 
nurses); (3) POC test manufacturers (employees of POC test 
manufacturers); (4) the general public; and (5) general prac-
titioners. The questionnaire remained open for online respon-
dents from 08/16/2011 to 06/22/2012; a total of 10 months. 
These target groups were approached using: (1) an online web-
site (www.tempotest-qc.eu); (2) a press release (“Join the fight 
against resistant bacteria!” by AlphaGalileo Foundation); (3) 
online social media, including YouTube (http://www.youtube.
com/watch?v=t1Ni8VtnFuI), and  relevant discussion groups 
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on Linked-In (www.linkedin.com); (4) an advertisement in a 
national Dutch free newspaper (Metro); (5) an advertisement in 
a local internal hospital newspaper (Ziekenhuiskrant); as well 
as (6) flyers and poster presentations at multiple European sci-
entific conferences ( Figure 1). The online and voluntary nature 
of the survey meant that we were unable to record the number 
of nonresponders. Moreover, the survey was designed so that 
all questions in the questionnaire had to be completed before 
the opinions of respondents could be successfully submitted.
statistical analysis
The association between the categorical variables (answer 
and group) was assessed using the Chi-square test or Fisher’s 
exact test when appropriate. Univariate logistic regression 
and odds ratio (OR) with 95% confidence intervals were 
calculated and used to compare the opinions of medical 
specialists and POCT manufacturers and the general public. 
Two sided P-values of ,0.05 were considered significant. 
All analyses were performed using the statistical software 
package R (free download from http://www.R-project.org/) 
version 2.15.1 (The R Foundation for Statistical Computing, 
Vienna, Austria).19 In order to increase the sample size for 
statistical analysis, the survey results of the hospital medi-
cal microbiologists target group (n = 91) were merged with 
the answers of the nonmicrobiology specialists (n = 39) and 
the combined group (n = 130) was referred to as “medical 
specialists”.
Ethical statement
This study did not involve categorizing humans by 
race/ethnicity, age, disease/disabilities, religion, sex/
gender, sexual orientation, or other socially constructed 
groupings. All results were collected anonymously 
using an online questionnaire which was available at 
www.TEMPOtest-QC.eu. The questionnaire asked 
volunteer respondents to provide their opinions on the 
development and potential hurdles to MM-POC testing. 
Although data was collected on country of employment, 
country of birth, and occupation, country of employ-
ment data was utilized to provide an indication of how 
successful the questionnaire “promotional campaign” 
was, and country of birth data was used to provide an 
indication of the geographical diversity of the respondent’s 
opinions. Both country of birth and country of employ-
Online questionnaire opened at www.TEMPOtest-QC.eu – 2011
Newspaper advertisement – metro (The Netherlands) – 10.2011
Online advertisement – www.rapidmicrobiology.com – 03.2011
Flyers – annual Dutch society for microbiology/medical microbiology meeting – 04.2011
Poster – European congress of clinical microbiology and infectious diseases meeting – 05.2011
Poster – European congress of clinical microbiology and infectious diseases meeting – 03.2012
Press release via AlphaGalileo – 04.12
Promotional video placed online on youtube at
http://www.youtube.com/watch?v=t1Ni8VtnFuI – 02.2012
Online questionnaire closed – 07.2012
20
12
20
11
Poster – Annual Dutch society for microbiology/medical microbiology meeting – 04.2011
Newspaper adverstisement – the hospital newspaper (Ziekenhuiskrant) – 10.2011
Poster – 7th European meeting on molecular diagnostics – 10.2011
Journal advertisement – general practitioner and science (Huisarts en Wetenschap) – 11.2011
Journal advertisement – Dutch journal for medical microbiology
(Nederlands tijdscjhrift voor medische microbiologie) – 12.2011
Figure 1 Table showing the timeline and activities associated with the dissemination of the TEMPOtest-QC questionnaire.
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ment data were not used in subsequent statistical analyses 
of the results. Full details regarding the TEMPOtest-QC 
study protocol and objectives of the study were available 
online on the same webpage as the link to the question-
naire, and there was no compulsion for interested parties 
to participate in the questionnaire. For all of these reasons 
ethical approval for the study was not requested from the 
host institution (Erasmus Medical Center, Rotterdam, The 
Netherlands).
Results
Respondent characteristics
Overall, 293 individuals responded to the survey within 
the 10 months that the questionnaire was available online, 
with 91 (31%) participants responding as medical specialist 
(medical microbiologists), 39 (13%) as medical specialist 
(nonmedical microbiologists), 25 (9%) as employees of POC 
test manufacturers and 138 (47%) responding as members 
of the general public (Figure 2A). The largest percentage of 
these participants were born and living in The Netherlands, 
though responses were also received from respondents born 
or living in Poland, Italy, the United Kingdom, Belgium, and 
France among others (Figure 2B and C). In total, responses 
were received from respondents born and/or currently work-
ing in 18 different European countries. Responses were also 
received from eleven general practitioners practicing in The 
Netherlands. However, these results have been omitted due to 
the low numbers of respondents in this target group. Of the 
medical microbiologist respondents, 24% reported to occasion-
ally use a POC diagnostic device for the diagnosis of infectious 
diseases. The majority (68%) of medical microbiological point-
of-care test (MM-POC) devices currently used were based on 
antibody related detection technologies.
POC infectious disease diagnostics  
and their specifications
As previously mentioned, the availability of POC diagnostics for 
(bacterial/fungal) infectious disease testing currently lags behind 
the availability of POC diagnostics in other fields of medicine, 
such as clinical chemistry and virology. Therefore, one of the first 
questions asked of the medical specialist (medical microbiologists 
and nonmicrobiologists) target groups was designed to obtain 
their opinions on how important an infectious disease (bacterial/
fungal) POC diagnostic device would be in helping diagnose 
various infectious disease-related conditions. The majority of 
respondents considered MM-POC devices most useful in the diag-
nosis of blood culture infections, followed by hospital acquired 
infections and respiratory infections (Figure 3). There was less 
enthusiasm for the detection of oral and urinary tract infections. 
Interestingly, when asked for their opinions on the use of such 
MM-POC devices within various medical environments, there 
was a generally favorable response of medical specialists, POCT 
developers, and the general public for the use of MM-POC diag-
nostics in the hospital ward and general practitioners’ surgeries. 
However, there appeared a sharp division in opinions on the use 
of MM-POC diagnostics at the patient’s home (Figure 4), with 
A
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Non-medical microbiology specialists
Hospital medical microbiologists
POCT manufacturers
General public
The Netherlands
Poland
Italy
United Kingdom
Belgium
France
Spain
Germany
Sweden
Portugal
Greece
Ireland
Estonia
Slovenia
Malta
Austria
Other
Figure 2 Profession (A), country born (B), and country of residence (C) of the 293 respondents who participated in the TEMPOtest-QC survey.
Abbreviation: POCT, point-of-care test.
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Figure 3 Mean responses of medical specialists regarding the current perceived necessity for MM-POC in relationship to type of disease. The majority regarded the 
development of MM-POC against both hospital acquired and blood culture infections as “Absolutely Necessary”.
Abbreviation: MM-POC, medical microbiological point-of-care tests.
Hospital wards M
M
M
P
P
G
G
0 10 20 30 40 50 60 70 80 90 100
Favorable Unfavorable No opinion
General practitioner
Patient’s home
Percentage (%)
Figure 4 Opinions of target groups regarding the use of infectious disease (bacterial/fungal) POC devices in different environments. Medical specialists (hospital medical 
microbiologists and nonmedical microbiology specialists) (M), POCT manufacturers (P), and the general public (G) regarding the applicability of MM-POC in hospital wards, 
at the general practitioner or at the patient’s home.
Abbreviations: G, general practitioners; M, medical specialists; P, POCT manufacturers; POCT, point-of-care test; MM-POC, medical microbiological point-of-care tests.
greater than 60% of the general public having a favorable opinion, 
compared to less than 20% of medical specialists.
When asked about their opinions regarding the actual 
specifications of bacterial/fungal POC diagnostics, medical 
specialists and POC manufacturers provided the responses 
shown in Table 1. Opinions on the most important factors 
with respect to an MM-POC device indicated that no single 
particular factor was considered most important in any of the 
target groups, though “reliability” and “time to diagnosis” 
tended to receive a large number of votes in both groups (both 
60.8%). Interestingly, specificity scored high (60.0%) in the 
medical specialists group but was least favored by the POC 
manufacturer group (44.0%). Regarding the most important 
factors of an MM-POC device, no significant difference in the 
opinion of medical specialists and POCT manufacturers was 
observed (P = 0.54). Medical specialists opted for test speci-
ficity that could distinguish between bacteria, viruses, fungi 
and no infection (57.7%) and class of antibiotic resistance 
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Table 1 Opinions of target groups regarding the most relevant specifications for bacterial or fungal point-of-care diagnostics
Medical specialists 
No (%)
POCT manufacturers  
No (%)
OR (95% CI) P-value
Respondents 130 25
1.  In your opinion, what are the most important factors with respect to infectious disease POCT? 
(multiple answers allowed).
  Costs 70 (53.8) 17 (68.0) – 0.543
  sensitivity 78 (60.0) 14 (56.0) – –
  Specificity 78 (60.0) 11 (44.0) – –
  simplicity 69 (53.1) 19 (76.0) – –
  Reliability 79 (60.8) 19 (76.0) – –
Time to diagnosis 79 (60.8) 21 (84.0) – –
2.  How specific should a bacterial or fungal POCT be? The test should be able to distinguish between: 
(multiple answers allowed).
  Bacteria/fungi/viruses/no infection 75 (57.7)  9 (36.0) – 0.543
   Bacterial or fungal species including  
genetic types/clones
56 (43.1) 16 (64.0) – –
  Class of antibiotic resistance 94 (72.3) 12 (48.0) – –
  No opinion 9 (6.9) 2 (8.0) – –
3. What would be your preferred maximum “time to diagnosis” for a bacterial or fungal POCT?
  0 minutes–5 minutes 10 (7.7) 4 (16.0) 0.40 (0.11–1.20) 0.121
  5 minutes–15 minutes 36 (27.7) 7 (28.0) 0.44 (0.11–1.93) 0.251
  15 minutes–1 hour 50 (38.5) 9 (36.0) 0.21 (0.04–1.12) 0.068
  .1 hour 32 (24.6) 3 (12.0) 0.42 (0.11–1.77) 0.206
4. Complexity: In your opinion, what is the maximum number of processing steps that should be performed when using a bacterial or fungal POCT?
  1 step 22 (16.9) 7 (28.0) 0.32 (0.13–0.71) 0.008
  2 steps 47 (36.2) 5 (20.0) 0.32 (0.09–1.11) 0.075
  3 steps 42 (32.3) 10 (40.0) 0.68 (0.23–2.10) 0.494
  .3 steps 16 (12.3) 3 (12.0) 0.45 (0.09–1.85) 0.289
Abbreviations: CI, confidence interval; No, number; OR, odds ratio; POCT, point-of-care test.
(72.3%). A similar result was obtained among the POCT 
manufacturers. Interestingly both target groups tended to 
agree that any such MM-POC test should possess a maximum 
“time-to-diagnosis” of 15 min–1 hour. In addition, according 
to the target groups, the maximum number of processing steps 
for an MM-POC device was considered as 2 to 3 processing 
steps, which on average, when combined with the maximum 
time-to-diagnosis results described above, would suggest that 
an MM-POC device should require an average processing 
time of approximately 15 minutes per step.
POC disease diagnosis at home  
and the quality of healthcare
Table 2 shows the opinions of hospital personnel and the 
general public to questions relating to POC infectious 
disease diagnosis at home and the perceptions of these 
target groups regarding the quality of POC healthcare. 
The large majority of both medical specialists and the 
general public thought that the introduction of bacterial 
or fungal POC diagnostic testing to the general practi-
tioner’s surgery, or within the patient’s own home, would 
affect the quality of patient care. However, the opinion 
on how patient care is affected signif icantly differed 
between the two target groups. The majority (72.5%) of 
the general public expects that the use of MM-POC will 
allow the doctor to better monitor their health compared 
to less than half (40.0%) of the medical specialists. The 
general public tended to be more positive regarding the 
effect of home POC testing on the doctor-patient relation-
ship than the medical specialists. In fact, most medical 
specialists thought that bacterial or fungal home-testing 
POC technologies would indeed affect the doctor-patient 
relationship, with the majority of these (37/62) believing 
that any effect would result in a negative rather than a 
positive impact. Also the opinions on interpretation of 
the MM-POC test results differed between the two target 
groups. Whereas most (53.1%) of the medical specialists 
expect problems in the interpretation of POC test results, 
a significantly smaller percentage (37.0%) of the general 
public foresees problems.
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Table 2 Opinions of target groups regarding the effect of point-of-care testing on the quality of health care
Medical specialists 
No (%)
General public 
No (%)
OR (95% CI) P-value
Respondents 130 138
1.  In your opinion, would the introduction of bacterial or fungal POC diagnostic testing to the general practitioner’s surgery, or within the patient’s 
own home, affect the quality of patient care?
  Yes 76 (58.5) 101 (73.2) 0.34 (0.15–0.71) 0.006
  No 28 (21.5) 28 (20.3) 2.79 (1.14–7.27) 0.028
  Don’t know 24 (18.5) 9 (6.5) 3.47 (1.59–8.22) 0.003
2.  Do you think that home-testing using bacterial or fungal POC testing technologies will allow you/the doctor to better monitor your patients/your 
health?
  Yes 52 (40.0) 100 (72.5) 1.75 (1.27–2.44) ,0.0001
  No 48 (36.9) 25 (18.1) 0.28 (0.15–0.49) ,0.0001
  Don’t know 28 (21.5) 13 (10.0) 0.24 (0.11–0.48) ,0.0001
3.  Do you think that home-testing using bacterial or fungal POC technologies will have an impact on the doctor-patient relationship?
  Yes (in a positive context) 25 (19.2) 48 (34.8) 1.66 (1.05–2.65) 0.032
  Yes (in a negative context) 37 (28.5) 30 (23.1) 0.45 (0.23–0.87) 0.019
  No 27 (20.8) 35 (25.4) 0.73 (0.37–1.43) 0.359
  Don’t know 39 (30.0) 25 (18.1) 0.37 (0.18–0.72) 0.004
0.014
4.  Do you think that there will be significant problems in interpreting the results of bacterial or fungal POCT?
  Yes 69 (53.1) 51 (37.0) 0.68 (0.47–0.97) 0.033
  No 33 (25.4) 47 (34.1) 1.87 (1.07–3.28) 0.028
  Don’t know 26 (20.0) 40 (29.0) 2.18 (1.20–4.02) 0.012
Abbreviations: CI, confidence interval; No, number; OR, odds ratio; POC, point-of-care; POCT, point-of-care test.
Infectious disease POC diagnostics  
and the general public
One of the questions in the survey was related to the effect 
of MM-POC on patient visits to the general practitioner. 
The majority of the general public respondents (46.4%) 
expect that the introduction of MM-POC tests will lead to 
a decrease in the number of visits they make to the general 
practitioner (Table 3). Additionally, if these MM-POC devices 
are to become available on the home testing market for the 
general public, information is required regarding the financial 
expectations of the general public towards the cost of such 
POC devices. The most favorable price for a single POC test 
currently lies between €5 to €10 (approximately $7.5–$12.5) 
per test (Table 3). Finally, 85.5% of the general public would 
be willing to purchase an MM-POC testing device at a phar-
macy, rather than at a supermarket, at a drugstore, or over 
the internet (Table 3).
Discussion
The worldwide introduction and frequent use of infectious 
disease POC diagnostic devices (including bacterial/fungal 
testing), will help reduce the global infectious disease burden 
and help reduce the continuing development and spread of 
antimicrobial resistances. The TEMPOtest-QC question-
naire revealed that the development of MM-POC devices 
for the diagnosis of blood borne, hospital acquired, and 
respiratory tract infections should have the highest priority 
for POCT manufacturers. Moreover we would recommend 
POCT manufacturers to target MM-POC devices which are 
able to distinguish between bacteria/fungi/viruses/ no infec-
tion, and/or class of antibiotic resistance, with a maximum 
“time-to-diagnosis” of 15–60 minutes, in which a maximum 
of 2–3 processing steps are involved. All factors regarding 
infectious disease POC listed in the survey were scored 
with an equal importance by both medical specialists and 
POCT manufacturers. Interestingly, the only exception was 
specificity; this factor scored highest in the medical special-
ists group but was least favored by the POCT manufacturer 
group. Perhaps this is a factor that needs to be re-considered 
by POCT developers and manufacturers?
Surprisingly, “costs” tended not to be a top priority 
for both groups, though this was possibly due to the fact 
that the medical specialists were considering the use of 
MM-POC devices within a medical environment (hospital 
or general practitioner’s surgery), rather than considering 
MM-POC devices intended for use in the much less mature 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
565
Point-of-care diagnostics in medical microbiology
Patient Preference and Adherence 2013:7
 “home-testing” environment. Perhaps encouraging for POC 
manufacturers, the price that the general public is willing to 
pay is above the current price for a single POC test as declared 
by POCT manufacturers (data not shown). Though of course 
this price may have been calculated using discounts available 
from high-volume sales and high-throughput sampling, as 
opposed to the single-use testing that will be required for 
consumers within their own home. The purchase of an MM-
POC device is by the majority of the general public favored 
at a pharmacy. This may be related to “trust issues”, the gen-
eral public perceiving medical products sold at pharmacies 
as being perhaps more “trustworthy” and of higher quality, 
as well as possibly valuing the expert advice available at 
pharmaceutical stores.
As a note of concern for POC manufacturers, respondents 
in the medical specialist and general public target groups 
were significantly different with respect to their opinions on 
whether there would be significant problems in interpreting 
the results of MM-POC diagnostic tests. In contrast, however, 
a clear majority of medical specialists thought that there 
would be significant problems in interpretation, a point of 
concern also raised in a previous study.20 These results indi-
cate that careful design, unambiguous result interpretation, 
and ready access to reliable and understandable diagnostic 
information is a prerequisite for building consumer confi-
dence in the use of POC diagnostics.
The authors acknowledge there is a bias in the national 
reporting levels between the different European countries in 
this study. However, at the moment there is no evidence to 
suggest that the opinions of Dutch and Polish responders are 
different to those of other European citizens. The authors also 
acknowledge that the responses from POCT manufacturers 
may be biased towards the rapid introduction of MM-POC 
devices to the infectious diseases diagnostic market. In fact, 
the responses from POCT manufacturers were similar to 
the opinions of those of medical professionals, and it is the 
favorable opinion of the general public, which is currently 
the driving force behind the development and implementation 
of such MM-POC devices.
In conclusion, in this survey, no significant differences 
were observed between the opinions of medical special-
ists and POC manufacturers regarding the most relevant 
specifications for MM-POC devices. However, interesting 
differences were observed in the responses to the introduc-
tion of MM-POC devices and their effect on the quality of 
healthcare, with the general public tending to be more opti-
mistic about the effect of MM-POC device implementation 
and subsequent improvement in the quality of healthcare 
compared to the medical specialists. All of the above men-
tioned issues need to be addressed, in order to successfully 
understand the current requirements and perceived hurdles 
to the implementation of MM-POC diagnostic devices into 
the medical, and possibly home environment.
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Table 3 Perceived effect of the introduction of bacterial or fungal 
point-of-care testing technologies according to the general public
General public 
No (%)
Respondents 138
1.  Do you think that home-testing using bacterial or fungal POCT 
technologies will likely increase or decrease the number of visits you 
make to your general practitioner?
  Increase 16 (11.6)
  Decrease 64 (46.4)
  Have no effect 39 (28.3)
  Don’t know 19 (13.8)
2.  If a home-testing kit for infectious diseases was available what is the 
maximum cost that you would be prepared to pay for a single test?
  € 0,– 6 (4.3)
  € 1,– to € 5 30 (21.7)
  € 5,– to € 10 54 (39.1)
  € 10,– to € 25 38 (27.5)
  € 25,– to € 50 6 (4.3)
  € 50,– to € 100 3 (2.2)
  .€ 100 1 (0.7)
3.  Where would you prefer to purchase an infectious disease home-
testing kit? 
(multiple choices allowed).
  Your local hospital 21 (15.2)
  General practitioner 42 (30.4)
  Pharmacy 118 (85.5)
  Drugstore 48 (34.8)
  supermarket 16 (11.6)
  Internet 19 (13.8)
Abbreviations: No, number; POCT, point-of-care test.
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Nonmedical microbiology specialist (hospital doctors and nurses)
Q no Labels Question Options
1. a) Do you use bacterial or fungal “point-of-care” test(s) for the diagnosis 
of infectious diseases at the moment?
Yes
No
b) If yes, which type of bacterial or fungal “point-of-care” test(s) do you 
use? (multiple answers allowed).
Nucleic acid based
Antibody based
Protein based
Metabolomic
Don’t know
Other
c) If no, would you be willing to use an bacterial or fungal “point-of-care” 
test in your hospital ward in the future?
Yes
No
Perhaps
Don’t know
2. In your opinion, what are the most important factors with respect to 
infectious disease “point-of-care” testing? (multiple answers allowed).
Costs
sensitivity
Specificity
simplicity
Reliability
Time to diagnosis
3. How specific should a bacterial or fungal “point-of-care” test be?  
The test should be able to distinguish between …
Bacteria or fungi or viruses or no infection only
Bacterial/fungal species
Bacterial/fungal sub-species and major genetic types 
and clones
Class of antibiotic resistance (eg, cephalosporin, 
aminoglycoside, fluoroquinolone, etc)
Actual antibiotic resistance gene present
No opinion
4. Please rank the following infectious diseases where you think a 
bacterial or fungal “point-of-care” test(s) would be particularly useful 
at the present moment in time.
Respiratory/gastrointestinal/sexually transmitted 
diseases/urinary tract infections/woundcare/oral 
infections/hospital acquired infections/blood culture 
infections
Absolutely necessary/probably useful/not useful/
no opinion
5. What would be your preferred maximum “time to diagnosis” for a 
bacterial or fungal “point-of-care” test?
0 minutes to 5 minutes
6 minutes to 15 minutes
16 minutes to 30 minutes
31 minutes to 60 minutes
1 to 2 hours
2 to 5 hours
.5 hours
6. Complexity: in your opinion, what is the maximum number of 
processing steps that should be performed when using a bacterial or 
fungal “point-of-care” test?
1 step
2 steps
3 steps
4 steps
.4 steps
7. What is your opinion on the introduction of bacterial or fungal  
“point-of-care” diagnostic testing within your own hospital wards?
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
8.  What would be your opinion if bacterial or fungal “point-of-care” 
testing became available within the general practitioner’s surgery?
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
(Continued)
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Nonmedical microbiology specialist (hospital doctors and nurses) (Continued)
Q no Labels Question Options
9. What would be your opinion if bacterial or fungal “point-of-care” 
testing became available within the patient’s own home (with patients 
able to perform their own diagnostic testing)?
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
10. a) In your opinion, would the introduction of bacterial or fungal “point-
of-care” testing to hospital wards (to be performed by nonmedical 
microbiology specialist doctors and nurses), affect your professional 
status?
Definitely yes
Yes
No
Definitely no
Don’t know
b) If yes, how do you think it would affect your professional status? Very positively
Positively
Negatively
Very negatively
Don’t know
11. Do you think that home-testing using bacterial or fungal point-of-care 
testing technologies will:
 
a) Allow you to better monitor your patients? Yes
No
Don’t know
b) Negatively affect your dealings with patients? Yes
No
Don’t know
c) Have impact on the doctor-patient relationship? Yes (in a positive context)
Yes (in a negative context)
No
Don’t know
12. Do you think that there will be significant problems in interpretating 
the results of bacterial or fungal “point-of-care” diagnostic tests?
Yes
No
Don’t know
13. In your opinion, would the introduction of bacterial or fungal “point-
of-care” diagnostic testing to the general practitioner’s surgery, or 
within the patient’s own home, affect the quality of patient care?
Definitely yes
Yes
No
Definitely no
Don’t know
14. What is your opinion on the following statements:
a) “Infectious disease home-testing kits are being developed that will 
allow people to test themselves at home without medical supervision 
for the presence of infectious diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
b) “Test-kits are being developed that will allow people to be tested at 
their own general practitioner’s surgery for the presence of infectious 
diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
15. Do you believe that the use of bacterial and fungal “point-of-care” 
test(s) will positively or negatively affect how patients view your 
profession?
Very positively
Positively
Negatively
Very negatively
Don’t know
No effect
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Hospital medical microbiologists including medical microbiology laboratory technicians
Q no Labels Question Options Option labels
1. a) Do you use bacterial or fungal “point-of-care” 
test(s) for the diagnosis of infectious diseases at the 
moment?
Yes
No
a
b
 b) If yes, which type of bacterial or fungal “point-of-
care” test(s) do you use? (multiple answers allowed).
Not applicable
Nucleic acid based
Antibody-based
Protein-based
Metabolomic
Don’t know
Other
a
b
c
d
e
f
c) If no, would you be willing to use an bacterial or 
fungal “point-of-care” test in your hospital ward in 
the future?
Yes
No
Perhaps
Don’t know
a
b
c
d
2. In your opinion, what are the most important factors 
with respect to infectious disease “point-of-care” 
testing? (multiple answers allowed).
Costs
sensitivity
Specificity
simplicity
Reliability
Time to diagnosis
a
b
c
d
e
f
3. How specific should a bacterial or fungal “point-of-
care” test be? The test should be able to distinguish 
between …
Bacteria or fungi or viruses or no infection only
Bacterial/fungal species
Bacterial/fungal sub-species and major genetic 
types and clones
Class of antibiotic resistance (eg, cephalosporin, 
aminoglycoside, fluoroquinolone, etc)
Actual antibiotic resistance gene present
No opinion
a
b
c
d
e
f
4.
 
Please rank the following infectious diseases where 
you think a bacterial or fungal “point-of-care” test(s) 
would be particularly useful at the present moment 
in time.
 
Respiratory/gastrointestinal/sexually transmitted 
diseases/urinary tract infections/woundcare/
oral infections/hospital acquired infections/blood 
culture infections
Absolutely necessary/probably useful/not useful/
no opinion
5. What would be your preferred maximum “time to 
diagnosis” for a bacterial or fungal “point-of-care” 
test?
0 minutes to 5 minutes
6 minutes to 15 minutes
16 minutes to 30 minutes
31 minutes to 60 minutes
1 to 2 hours
2 to 5 hours
.5 hours
a
b
c
d
e
f
g
6. Complexity: in your opinion, what is the maximum 
number of processing steps that should be 
performed when using a bacterial or fungal “point-
of-care” test?
1 step
2 steps
3 steps
4 steps
.4 steps
a
b
c
d
e
7. What is your opinion on the introduction of 
bacterial or fungal “point-of-care” diagnostic testing 
within your own hospital wards?
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
8. What is your opinion on the introduction of 
bacterial or fungal “point-of-care” diagnostic testing 
to the general practitioner’s surgery?
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
(Continued)
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Hospital medical microbiologists including medical microbiology laboratory technicians (Continued)
Q no Labels Question Options Option labels
9. What would be your opinion if bacterial or fungal 
“point-of-care” diagnostic testing became available 
within the patient’s own home (with patients able to 
perform their own diagnostic testing)?
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
10. a) In your opinion, would the introduction of bacterial 
or fungal “point-of-care” testing to hospital wards (to 
be performed by nonmedical microbiology specialist 
doctors and nurses), affect your professional status?
Definitely yes
Yes
No
Definitely no
Don’t know
a
b
c
d
e
b) If yes, how do you think it would affect your 
professional status?
Very positively
Positively
Negatively
Very negatively
Don’t know
a
b
c
d
e
11. Do you think that home-testing using bacterial or 
fungal “point-of-care” testing technologies will:
a) Allow you to better monitor your patients’ health? Yes
No
Don’t know
a
b
c
b) Allow patients to better monitor their health? Yes
No
Don’t know
a
b
c
c) Increase or decrease the number of visits patients 
make to their general practitioner?
Greatly increase
Increase
Decrease
Greatly decrease
Have no effect
Don’t know
a
b
c
d
e
f
d) Impact on the doctor-patient relationship? Yes (in a positive context)
Yes (in a negative context)
No
Don’t know
a
b
c
d
12. Do you think that there will be significant problems 
in interpretating the results of bacterial or fungal 
“point-of-care” diagnostic tests?
Yes
No
Don’t know
a
b
c
13. In your opinion, would the introduction of bacterial 
or fungal “point-of-care” diagnostic testing to the 
general practitioner’s surgery, or within the patient’s 
own home, affect the quality of patient care?
Definitely yes
Yes
No
Definitely no
Don’t know
a
b
c
d
e
14.  What is your opinion on the following statements:   
a) “Infectious disease home-testing kits are being 
developed that will allow people to test themselves 
at home without medical supervision for the 
presence of infectious diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
b) “Test-kits are being developed that will allow people 
to be tested at their own general practitioner’s 
surgery for the presence of infectious diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
15. Do you believe that the use of bacterial and fungal 
point-of-care test(s) will positively or negatively 
affect how patients view your profession?
Very positively
Positively
Negatively
Very negatively
Don’t know
No effect
a
b
c
d
e
f
(Continued)
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Hospital medical microbiologists including medical microbiology laboratory technicians (Continued)
Q no Labels Question Options Option labels
16. In your opinion, would the introduction of bacterial 
or fungal “point-of-care” diagnostic testing to the 
general practitioner’s surgery, or within the patient’s 
own home, affect the jobs of currently employed 
medical microbiologists?
Definitely yes
Yes
No
Definitely no
Don’t know
a
b
c
d
e
17. In your opinion, would there still be a role for 
qualified hospital medical microbiologists and 
trained medical microbiology diagnostic laboratory 
technicians if bacterial or fungal “point-of-care” 
diagnostic testing became widely available and used in 
hospital wards, in general practitioners surgeries, and 
at home by patients?
Definitely yes
Yes
No
Definitely no
Don’t know
a
b
c
d
e
Point-of-care test manufacturers
Q no Labels Question Options Option labels
1.  Which type of bacterial or fungal “point-of-
care” test (including tests available to general 
practitioners, hospital laboratories, and in the 
home) do you currently have available on the 
market? (multiple answers allowed).
Nucleic acid based
Antibody based
Protein based
Metabolomic
Other
No test currently available
a
b
c
d
e
f
2. In your opinion, what are the most important 
factors with respect to infectious disease 
“point-of-care” testing? (multiple answers 
allowed).
Costs
sensitivity
Specificity
simplicity
Reliability
Time to diagnosis
a
b
c
d
e
f
3. How specific should a bacterial or fungal  
“point-of-care” test be? The test should be  
able to distinguish between …
Bacteria or fungi or viruses or no 
infection only
Bacterial/fungal species
Bacterial/fungal sub-species and major 
genetic types and clones
Class of antibiotic resistance (eg, 
cephalosporin, aminoglycoside, 
fluoroquinolone, etc)
Actual antibiotic resistance gene 
present
No opinion
a
b
c
d
e
f
4. a) For which disease type(s) have you developed, 
or are you developing, a “point-of-care” test? 
(multiple answers allowed).
Respiratory
Gastrointestinal
sexually transmitted diseases
Urinary tract infections
Woundcare
Oral infections
Hospital acquired infections
Blood culture infections
None
Confidential
a
b
c
d
e
f
g
h
i
j
b) Which infectious disease type is likely to be 
most profitable for manufacturers of infectious 
disease “point-of-care” tests? Please rank in 
order of importance.
Respiratory
Gastrointestinal
sexually transmitted diseases
Absolutely necessary/probably 
useful/not useful/no opinion
Absolutely necessary/probably 
useful/not useful/no opinion
Absolutely necessary/probably 
useful/not useful/no opinion
(Continued)
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Point-of-care test manufacturers (Continued) 
Q no Labels Question Options Option labels
Urinary tract infections
Woundcare
Oral infections
Hospital acquired infections
Blood culture infections
Absolutely necessary/probably 
useful/not useful/no opinion
Absolutely necessary/probably 
useful/not useful/no opinion
Absolutely necessary/probably 
useful/not useful/no opinion
Absolutely necessary/probably 
useful/not useful/no opinion
Absolutely necessary/probably 
useful/not useful/no opinion
5. How long do you estimate the time to diagnosis 
for your bacterial or fungal “point-of-care” test 
to be?
0 minutes to 5 minutes
6 minutes to 15 minutes
16 minutes to 30 minutes
31 minutes to 60 minutes
1 to 2 hours
2 to 5 hours
.5 hours
Not known
Confidential
Not applicable
a
b
c
d
e
f
g
h
i
j
6. Complexity: in your opinion, what is the 
maximum number of processing steps that 
should be performed when using a bacterial or 
fungal “point-of-care” test?
1 step
2 steps
3 steps
4 steps
.4 steps
a
b
c
d
e
7. How much does your “point-of-care” cost  
(per test) on the market (in euro)?
€ 0,– per test
€ 1,– to € 5,– per test
€ 6,– to € 10,– per test
€ 11,– to € 25,– per test
€ 26,– to € 50,– per test
€ 51,– to € 100,– per test
.€ 100,– per test
Not known
Confidential
Not applicable
a
b
c
d
e
f
g
h
i
j
8. In your opinion, would the introduction of 
bacterial or fungal “point-of-care” diagnostic 
testing to the general practitioner’s surgery, or 
within the patient’s own home, affect the quality 
of patient care?
Definitely yes
Yes
No
Definitely no
Don’t know
a
b
c
d
e
9. What is your opinion on the following statements:
a) “Infectious disease home-testing kits are 
being developed that will allow people to 
test themselves at home without medical 
supervision for the presence of infectious 
diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
b) “Test-kits are being developed that will allow 
people to be tested at their own general 
practitioner’s surgery for the presence of 
infectious diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
10. Do you believe that the use of bacterial and 
fungal point-of-care test(s) will positively 
or negatively affect how patients view your 
profession?
Very positively
Positively
Negatively
Very negatively
Don’t know
No effect
a
b
c
d
e
f
(Continued)
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Point-of-care test manufacturers (Continued) 
Q no Labels Question Options Option labels
11. Which type of bacterial or fungal “point-of-
care” test (including tests available to general 
practitioners, hospital laboratories, and in the 
home) are you currently developing? (multiple 
answers allowed).
Nucleic acid based
Antibody based
Protein based
Metabolomic
Other
No test currently available
Confidential
a
b
c
d
e
f
g
12. For which market have you, or are you, 
developing your bacterial or fungal “point-of-
care” tests?
General practitioners
Hospital laboratories
Home use
Confidential
Not applicable
a
b
c
d
e
13.  Which factors would/do you take into 
consideration if/when developing new bacterial 
or fungal “point-of-care” tests? Please rank in 
importance.
size of target audience
Profit margin
Prevalence of disease
Costs of manufacture
Ease of use for the end-user
Costs of kit development
Reputation of kit manufacturer
a
b
c
d
e
f
g
14.  Which factor(s) do you think are the most 
important in influencing hospitals and general 
practitioners to use bacterial or fungal “point-
of-care” tests for a diagnostics laboratory? 
Please rank in importance.
Cost per test
simplicity of test methodology
speed of diagnosis
Robustness and reliability of the test kit
Ease of use for the end-user
Reputation of the manufacturer
sensitivity
Specificity
a
b
c
d
e
f
g
h
General public
Q no Labels Question Options Option labels
1. What is your opinion on the use of infectious disease home-testing-kits that 
would allow you to monitor your health at home?
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
2.   If a home-testing kit for infectious diseases was available, what is the 
maximum time that you would be prepared to wait for a result?
0 minutes to 5 minutes
6 minutes to 15 minutes
16 minutes to 30 minutes
31 minutes to 60 minutes
1 to 2 hours
2 to 5 hours
.5 hours
a
b
c
d
e
f
g
3. If a home-testing kit for infectious diseases was available (and you had to 
purchase the kit yourself) what is the maximum cost that you would be 
prepared to pay for a single test (in euro)?
€ 0,– per test
€ 1,– to € 5,– per test
€ 6,– to € 10,– per test
€ 11,– to € 25,– per test
€ 26,– to € 50,– per test
€ 51,– to € 100,– per test
.€ 100,– per test
a
b
c
d
e
f
g
4.  Do you think that home-testing using bacterial or fungal “point-of-care” 
testing technologies will:
  
a) Allow you to better monitor your health? Yes
No
Don’t know
a
b
c
(Continued)
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General public (Continued) 
Q no Labels Question Options Option labels
b) Allow a doctor to better monitor your health? Yes
No
Don’t know
a
b
c
c) Likely increase or decrease the number of visits you make to your general 
practitioner?
Greatly increase
Increase
Decrease
Greatly decrease
Have no effect
Don’t know
a
b
c
d
e
f
d) Impact on the doctor-patient relationship? Yes (in a positive context)
Yes (in a negative context)
No
Don’t know
a
b
c
d
5. Do you think that there will be significant problems in interpretating the 
results of bacterial or fungal “point-of-care” diagnostic tests?
Yes
No
Don’t know
a
b
c
6. In your opinion, would the introduction of bacterial or fungal “point-of-care” 
diagnostic testing to the general practitioner’s surgery, or within the patient’s 
own home, affect the quality of your health care?
Definitely yes
Yes
No
Definitely no
Don’t know
a
b
c
d
e
7.  What is your opinion on the following statements:
a) “Infectious disease home-testing kits are being developed that will allow 
people to test themselves at home without medical supervision for the 
presence of infectious diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
b) “Test-kits are being developed that will allow people to be tested at their 
own general practitioner’s surgery for the presence of infectious diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
a
b
c
d
e
8. If not available for free, where would you prefer to buy an infectious 
disease home-testing kit? (multiple choices allowed).
Your local hospital
General practitioner
Pharmacy
Drugstore
supermarket
Internet
a
b
c
d
e
f
General practitioners
Q no Labels Question Options
1. a) Do you use bacterial or fungal “point-of-care” test(s) for the 
diagnosis of infectious diseases at the moment?
Yes
No
b) If yes, which type of bacterial or fungal “point-of-care” test(s) 
do you use? (multiple answers allowed).
Nucleic acid based
Antibody based
Protein based
Metabolomic
Don’t know
Other
c) If no, would you consider using and infectious disease  
“point-of-care” test in your practice in the future?
Yes
No
Perhaps
Don’t know
(Continued)
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General practitioners (Continued)
Q no Labels Question Options
2. In your opinion, what are the most important factors with 
respect to bacterial or fungal “point-of-care” testing? (multiple 
answers allowed).
Costs
sensitivity
Specificity
simplicity
Reliability
Time to diagnosis
3. How specific should a bacterial or fungal “point-of-care” test 
be? The test should be able to distinguish between …
Bacteria or fungi or viruses or no infection only
Bacterial/fungal species
Bacterial/fungal sub-species and major genetic types and 
clones
Class of antibiotic resistance (eg, cephalosporin, 
aminoglycoside, fluoroquinolone, etc)
Actual antibiotic resistance gene present
No opinion
4. Please rank the following infectious diseases where you think 
bacterial or fungal “point-of-care” test(s) would be particularly 
useful at the present moment in time.
Respiratory/gastrointestinal/sexually transmitted diseases/
urinary tract infections/woundcare/oral infections/hospital 
acquired infections/blood culture infections
Absolutely necessary/probably useful/not useful/no opinion
5. What would be the maximum useful “time to diagnosis” for an 
bacterial or fungal “point-of-care” test? 
0 minutes to 5 minutes
6 minutes to 15 minutes
16 minutes to 30 minutes
31 minutes to 60 minutes
1 to 2 hours
2 to 5 hours
.5 hours
6. Complexity: in your opinion, what is the maximum number 
of processing steps that should be performed when using a 
bacterial or fungal “point-of-care” test?
1 step
2 steps
3 steps
4 steps
.4 steps
7. What in your opinion should be the current maximum cost 
per test for a bacterial or fungal “point-of-care” test (in euro)?
€ 0,– per test
€ 1,– to € 5,– per test
€ 6,– to € 10,– per test
€ 11,– to € 25,– per test
€ 26,– to € 50,– per test
€ 51,– to € 100,– per test
.€ 100,– per test
8. What is your opinion on the introduction of bacterial or fungal 
“point-of-care” diagnostic testing to the general practitioner’s 
surgery?
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
9. What would be your opinion if bacterial or fungal “point-of-
care” diagnostic testing became available within the patient’s 
own home (with patients able to perform their own diagnostic 
testing)?
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
10. Do you think that home-testing using bacterial or fungal 
“point-of-care” testing technologies will:
 
a) Allow you to better monitor your patients’ health? Yes
No
Don’t know
b) Allow patients to better monitor their health? Yes
No
Don’t know
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General practitioners (Continued)
Q no Labels Question Options
c) Increase or decrease the number of visits patients make to 
their general practitioner?
Greatly increase
Increase
Decrease
Greatly decrease
Have no effect
Don’t know
d) Impact on the doctor-patient relationship? Yes (in a positive context)
Yes (in a negative context)
No
Don’t know
11. Do you think that there will be significant problems in 
interpretating the results of bacterial or fungal “point-of-care” 
diagnostic tests?
Yes
No
Don’t know
12. In your opinion, would the introduction of bacterial or fungal 
“point-of-care” diagnostic testing to the general practitioner’s 
surgery, or within the patient’s own home, affect the quality of 
patient care?
Definitely yes
Yes
No
Definitely no
Don’t know
13. What is your opinion on the following statements:  
a) “Infectious disease home-testing kits are being developed that 
will allow people to test themselves at home without medical 
supervision for the presence of infectious diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
b) “Test-kits are being developed that will allow people to be 
tested at their own general practitioner’s surgery for the 
presence of infectious diseases?”
Very favorable
Favorable
Unfavorable
Very unfavorable
No opinion
14. Do you believe that the use of bacterial and fungal point-of-
care test(s) will positively or negatively affect how patients 
view your profession?
Very positively
Positively
Negatively
Very negatively
Don’t know
No effect
15.  Do you believe that the use of bacterial and fungal point-of-
care test(s) will positively or negatively affect:
 
a) Your health budget? Very positively
Positively
Negatively
Very negatively
No change
Don’t know
 b) The number of patient visits you receive? Very positively
Positively
Negatively
Very negatively
No change
Don’t know
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